Estimated cost of universal public coverage of prescription drugs in Canada

CMAJ

Volumn 187, Issue 7, 2015, Pages 491-497

  Morgan, Steven G ^a   Law, Michael ^a   Daw, Jamie R ^b   Abraham, Liza ^c   Martin, Danielle ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; CANADA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE PLANNING; HUMAN; ORGANIZATION AND MANAGEMENT; PRESCRIPTION; PUBLIC HEALTH INSURANCE; UNIVERSAL PHARMACARE; COST; COST OF ILLNESS; DRUG THERAPY; ECONOMICS; HEALTH INSURANCE; INSURANCE;

CANADA; COST OF ILLNESS; COST SAVINGS; COSTS AND COST ANALYSIS; DRUG THERAPY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PRESCRIPTION DRUGS; PRIVATE SECTOR; UNIVERSAL COVERAGE;

EID: 84928473986     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.141564     Document Type: Article

References (43)

1. Evans DB, Etienne C. Health systems financing and the path to universal coverage. Bull World Health Organ 2010;88:402.
2. Marchildon GP. Health systems in transition: Canada. Toronto: University of Toronto Press; 2006.
3. Royal Commission on Health Services. Ottawa: Queen's Printer; 1964.
4. Canada health action: building on the legacy. Vol. II. Ottawa: Health Canada; 1997.
5. Romanow RJ. Building on values: the future of health care in Canada - final report. Saskatoon: Commission on the Future of Health Care in Canada; 2002.
6. Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy 2012;104:19-26.
7. National health expenditure trends, 1975 to 2013. Ottawa: Canadian Institute for Health Information; 2013.
8. Hoskins E. Why Canada needs a national pharmacare program. The Globe and Mail [Toronto] 2014 Oct. 14.
9. Stanbrook MB, Hébert PC, Coutts J, et al. Can Canada get on with national pharmacare already? CMAJ 2011;183:E1275.
10. Dutt M. Affordable access to medicines: a prescription for Canada. Toronto: Canadian Doctors for Medicare; 2014.
11. Kennedy J, Morgan S. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 international health policy survey in seven countries. Clin Ther 2009;31:213-9.
12. Law MR, Cheng L, Dhalla IA, et al. The effect of cost on adherence to prescription medications in Canada. CMAJ 2012;184:297-302.
13. Morgan SG, Daw JR, Law MR. Rethinking pharmacare in Canada. Toronto: CD Howe Institute; 2013.
14. Demers V, Melo M, Jackevicius C, et al. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ 2008;178:405-9.
15. Law MR, Daw JR, Cheng L, et al. Growth in private payments for health care by Canadian households. Health Policy 2013;110:141-6.
16. Boothe K. How the pace of change affects the scope of reform: pharmaceutical insurance in Canada, Australia, and the United Kingdom. J Health Polit Policy Law 2012;37:779-814.
17. Daw JR, Morgan SG, Collins PA, et al. Framing incremental expansions to public health insurance systems: the case of Canadian pharmacare. J Health Polit Policy Law 2014;39:295-330.
18. Gagnon MA. A roadmap to a rational pharmacare policy in Canada. Ottawa: Canadian Federation of Nurses Unions; 2014.
19. National pharmacare cost impact study. Ottawa: Palmer D'Angelo Consulting; 1997.
20. Cost impact study of a national pharmacare program for Canada: an update to the 1997 report. Ottawa: Palmer D'Angelo Consulting; 2002.
21. Morgan SG, Smolina K, Mooney D, et al. The Canadian Rx atlas, 3rd edition. Vancouver: UBC Centre for Health Services and Policy Research; 2013.
22. Morgan S. Sources of variation in provincial drug spending. CMAJ 2004;170:329-30.
23. Morgan S. Drug spending in Canada: recent trends and causes. Med Care 2004;42:635-42.
24. Morgan SG. Prescription drug expenditures and population demographics. Health Serv Res 2006;41:411-28.
25. Aaserud M, Dahlgren AT, Kosters JP, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006;(2): CD005979.
26. Morgan S, Hanley G, McMahon M, et al. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthc Policy 2007;3:e121-40.
27. Morgan S, Daw J, Thomson P. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies. Health Aff (Millwood) 2013;32:771-7.
28. Contoyannis P, Hurley J, Grootendorst P, et al. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Econ 2005;14:909-23.
29. Patented Medicine Prices Review Board annual report 2013. Ottawa: Patented Medicine Prices Review Board; 2014.
30. Generic drugs in Canada, 2013. Ottawa: Patented Medicine Prices Review Board; 2014.
31. Pharmacists in Canada. Ottawa: Canadian Pharmacists Association; 2014. Available: www.pharmacists.ca/index.cfm/pharmacy - in-canada/pharmacists-in-canada/(accessed 2014 Oct. 20)
32. OECD health statistics 2014 - frequently requested data. Paris: OECD; 2014. Available: www.oecd.org/health/health-systems/oecd-health-statistics-2014-frequently-requested-data.htm (accessed 2014 July 31).
33. Kesselheim AS, Huybrechts KF, Choudhry NK, et al. Prescription drug insurance coverage and patient health outcomes: a systematic review. Am J Public Health 2015;105:e17-30.
34. Morgan S, Cunningham C. The effect of evidence-based drug coverage policies on pharmaceutical R&D: a case study from British Columbia. Healthc Policy 2008;3:54-63.
35. Structural Analysis (STAN) Databases. R&D expenditures by Industry. Paris: OECD; 2012. Available: http://stats.oecd.org/(accessed 2013 Feb. 17).
36. Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction medicare beneficiaries. Circulation 2008;117:1261-8.
37. Dhalla IA, Smith MA, Choudhry NK, et al. Costs and benefits of free medications after myocardial infarction. Healthc Policy 2009;5:68-86.
38. Drug use among seniors on public drug programs in Canada, 2012. Ottawa: Canadian Institute for Health Information; 2014.
39. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010;69:543-52.
40. Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol 2012;68:1425-33.
41. Hashim S, Gomes T, Juurlink D, et al. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones. J Popul Ther Clin Pharmacol 2013;20:e238-42.
42. Sketris IS, Lummis H, Langille E. Optimal prescribing and medication use in Canada: challenges and opportunities. Toronto: Health Council of Canada; 2007.
43. Ensuring the accessibility, affordability and sustainability of prescription drugs in Canada. Toronto: Canadian Life and Health Insurance Association; 2013.